Clarification of Answer by
bobbie7-ga
on
12 Jan 2005 20:13 PST
Dear Bru61,
Thank you for your clarification.
The survival rates range from six months to five years for different
types of MDS. Patients with high-risk MDS generally survive less than
two years
Relevant Excerpt
?According to the Leukemia & Lymphoma Society (U. S.), and the the
American Cancer Society (U. S.) at least 10,000 -14,000 new cases of
myelodysplastic syndrome (MDS) are diagnosed annually in the U. S.
There are an estimated over 300,000 patients with MDS, and 50,000 new
cases of MDS world-wide each year. The survival rates are ranging from
six months to five years for different types of MDS. Patients with
high-risk MDS generally survive less than two years.?
Bioscorpio.com http://64.233.161.104/search?q=cache:KVdBGxzJr6oJ:www.bioscorpio.com/leukemia.htm++MDS+survival+rates+%22*+years%22&hl=en
From the American Cancer Society :
?A system has been developed for staging MDS called the International
Prognostic Scoring System (IPSS). The system rates 3 factors: (1) the
percentage of blasts in the bone marrow; (2) whether chromosome
abnormalities are present and, if so, which ones; and (3) how low the
patient's blood counts are. These are given a score; the lowest scores
have the best outlook for survival.?
?For example, if your blast percentage is normal, your chromosomes are
normal, and your blood counts are only mildly reduced, your average
survival, if you are younger than age 60, would be around 12 years.
But age changes survival, so if you are older than 70, for example,
your average survival would only be 4 years. If, on the other hand,
you had a high blast count, abnormal chromosomes, and low blood
counts, you would have a high score and an average survival of less
than 1 year.?
?To summarize the significance of these factors, the IPSS groups
people with MDS into 4 categories of increasingly serious prognosis:
low risk (score=0), intermediate (INT)-1 (score=0.5-1) risk, INT-2
(score=1.5-2) risk, and high risk (score=2.5 or greater).?
Below is a table for the classifications and the median survival:
Median survival in years
AGE LOW RISK INT-1 INT-2 HIGH RISK
Below 60 11.8 5.2 1.8 0.3 (less than 4 months)
Above 60 4.8 2.7 1.1 0.5 (6 months)
American Cancer Society
http://www.cancer.org/docroot/cri/content/cri_2_4_3x_how_is_myelodysplastic_syndrome_staged_65.asp
Mean survival rates are from approximately six months to six years for
the different classifications of MDS.
Excerpt:
?Myelodysplastic syndromes (MDS) are a group of hematologic
malignancies that affect approximately 300,000 people worldwide.
Myelodysplastic syndromes occur when blood cells remain in an immature
or "blast" stage within the bone marrow and never develop into mature
cells capable of performing their necessary functions. Eventually, the
bone marrow may be filled with blast cells suppressing normal cell
development. According to the American Cancer Society 10,000 to 20,000
new cases of MDS are diagnosed each year in the United States, with
mean survival rates ranging from approximately six months to six years
for the different classifications of MDS. MDS patients must often rely
on blood transfusions to manage symptoms of anemia and fatigue until
they develop life-threatening iron overload and or toxicity, thus
underscoring the critical need for new therapies targeting the cause
of the condition rather than simply managing its symptoms.?
Doctor's Guide: December 6, 2004
http://www.docguide.com/dg.nsf/PrintPrint/9B978CB5410D21DD85256F6200527659
?According to the American Cancer Society and the Aplastic Anemia and
MDS International Foundation, there are an estimated 10,000-30,000 new
cases of MDS
in the United States each year. Survival rates range from six months
to many years for the different subtypes of MDS.?
Source:
Prohost Research
Breakthrough News
MAY 20, 2004
Myelodysplastic Syndrome (MDS)
http://www.prohostonline.com/ImpactingNews/IN%205%2020%2004.pdf
From the Association of Online Cancer Resources:
?A variety of risk classification systems have been developed to
predict the overall survival of patients with MDS and the evolution
from MDS to AML. These classification systems include the
French-American-British classification, the Bournemouth score,the Sanz
score, the Lille score, and the World Health Organization (WHO)
classification. Clinical variables included in these systems have
included bone marrow and blood myeloblast percentage, specific
cytopenias, age, lactate dehydrogenase level, and bone marrow
cytogenetic pattern.?
?An International MDS Risk Analysis Workshop was convened and the
clinical data from 816 patients with primary MDS from 7 previously
reported studies, which used independent risk-based prognostic
systems, were combined and collated. The combined data were analyzed
centrally and a global analysis was performed, forming the basis of a
new prognostic system called the International Prognostic Scoring
System (IPSS) for MDS. In multivariate analysis, significant
predictors for both survival and AML evolution included bone marrow
blast percentage, number of peripheral blood cytopenias, and
cytogenetic subgroup.?
?These data are used to assign MDS patients a score, which stratifies
patients into 1 of 4 risk groups: low-risk, intermediate-1,
intermediate-2, and high-risk.?
?The time for the development of AML in these risk groups was 9.4
years, 3.3 years, 1.1 years, and 0.2 years, respectively.?
?Median survival for these groups was 5.7 years, 3.5 years, 1.2 years,
and 0.4 years, respectively. This system has rapidly become
incorporated into clinical trial design for MDS.?
Association of Online Cancer Resources
http://www.acor.org/cnet/62929.content.tmp
I hope this additional information is useful.
Best regards,
Bobbie7
,
0 Comments
)